Gabrielle R. Kolakowski

Author

Also Known As

G.R. Kolakowski, Gabrielle Kolakowski, Gabrielle R. Kolakowski

Publications

777

Citations

H-Index

Concepts

All Affiliations

Gabrielle R. Kolakowski is an author at Loxo Oncology at Lilly (United States) specializing in medicine, drug discovery, and pharmacology.

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	57
2	Natural Sciences	1	1	39
3	Biochemistry	1	1	39
4	Chemical Biology	1	1	39
5	Molecular Biology	1	1	18

Gabrielle R. Kolakowski

Publications

759

Citations

H-Index

Page 1

	Year	Citations
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors Alexander Drilon, Ramamoorthy Nagasubramanian, James F. Blake, Cancer Discovery	2017	419
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies Benjamin Solomon, Lavinia Tan, Stephen Q. Wong, Journal of Thoracic Oncology	2020	272
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2 James F. Blake, John J. Gaudino, Jason De Meese, Bioorganic & Medicinal Chemistry Letters Combinatorial ChemistryMedicinal ChemistryBiochemistryNatural SciencesMedicine	2014	39
Abstract 1464: Pre-clinical characterization of potent and selective next-generation RET inhibitors Gabrielle R. Kolakowski, Erin D. Anderson, Joshua A. Ballard, Cancer Research Chemoprevention StrategyAbstract 1464Molecular BiologyPharmacotherapyPre-clinical Pharmacology	2021	18
Abstract P142: Preclinical characterization of LOX-22783, a highly potent, mutant-selective and brain-penetrant allosteric PI3Kα H1047R inhibitor Anke Klippel, Rui Wang, Loredana Puca, Molecular Cancer Therapeutics	2021	11

Page 1